The HealthTech industry is at a pivotal moment, with groundbreaking innovations reshaping the future of healthcare. From AI-driven drug discovery to precision medicine and advanced therapeutics, the sector is witnessing rapid evolution. However, navigating this landscape requires more than just technological breakthroughs—it demands a deep understanding of regulatory pathways, business scalability, and strategic partnerships. 

Shubham Jhuria, CFO & Partner at Aeravti Ventures, in an exclusive conversation with Dr. Asawari Savant, from Elets News Network (ENN), shed light on what it takes for startups to succeed in this space. Edited excerpts as follows

What unique criteria does Aeravti Ventures use to evaluate health tech startups for investment?

Aeravti Ventures takes a deep, conviction-driven approach to evaluating HealthTech startups, particularly in high-impact areas. Assessing any HealthTech or BioTech innovation involves a multi-faceted approach, including scrutinizing scientific validity, regulatory pathways, global applicability, competitive landscape, and business fundamentals.

However, a significant part of our evaluation is centered on ecosystem and founder validation. We leverage our extensive network of clinicians, doctors, health-focused businesses, and researchers—many of whom are part of our Entrepreneur Partner pool—to gain critical insights and ensure robust due diligence.

How does Aeravti leverage its extensive network to support health tech innovators?

At Aeravti Ventures, we are intentional about backing a select number of companies, ensuring that we can provide extensive support—either directly or through our network. We take this commitment seriously.

Our network spans healthcare, biotech, and the broader venture ecosystem, allowing us to bring in the right experts based on the unique needs of each portfolio company. This includes connections with pharmaceutical companies, clinical researchers, biotech executives, regulatory advisors, and medical device manufacturers. Our support covers critical areas such as distribution, refining clinical strategies, technology validation, and navigating regulatory approval processes, empowering founders to scale effectively.

In what ways does Aeravti’s experience in other sectors, like DeepTech and AgriTech, influence its approach to health tech investments?

At Aeravti Ventures, we adhere to core investment principles across all industries, with a strong focus on founder evaluation, technology validation, and business scalability. While these fundamentals remain constant, each sector introduces additional considerations based on its unique dynamics and stage of development.

Our experience in DeepTech and AgriTech has instilled in us the patience required to support businesses with long development cycles, reinforcing the importance of conviction over time. Additionally, investing in DeepTech has sharpened our ability to assess groundbreaking innovations, enabling us to take bolder, more forward-looking bets in HealthTech—such as backing disruptive solutions in drug discovery.

Can you discuss any successful health tech companies in your portfolio and what made them stand out?

Aeravti Ventures has invested in East Ocyon Bio, a pioneering company developing CAR-NK cell therapies to revolutionize cancer treatment. With cancer cases rising rapidly across India and the globe, East Ocyon Bio’s mission to transform critical care in this space stood out as a game-changer.

At Aeravti, we seek companies that don’t just innovate but have the vision and execution capability to reshape industries. In the HealthTech domain, East Ocyon Bio is a testament to that philosophy.

Also Read :- Top Companies Offering Instant Online Hearing Tests in India

How does Aeravti support health tech founders beyond just capital investment?

At Aeravti Ventures, we are committed to providing comprehensive support to our founders across all domains, including HealthTech. Our goal is to identify key challenges and opportunities for each company and empower them through a combination of strategic interventions, industry connections, and operational guidance. This can be simplified into two aspects:

Industry Access – Facilitating go-to-market strategies, market access, research partnerships, and regulatory navigation to help startups scale efficiently.

Mentorship & Guidance – Providing hands-on support in business modeling, compliance, talent acquisition, fundraising, and long-term strategic planning.

Beyond these, we actively leverage our network of experts, investors, and industry leaders to ensure our portfolio companies have the right resources at every stage of growth. Our commitment is not just to invest but to accelerate the journey of transformative startups.

What trends in the health tech sector excite you as a venture capitalist?

The HealthTech sector is evolving rapidly, but what excites me most is the convergence of HealthTech and DeepTech. The integration of AI in drug discovery is already transforming how new therapies are identified, significantly reducing time and costs. Additionally, advancements in drug delivery systems, particularly through nanotechnology and advanced materials, are opening up new frontiers in targeted and more effective treatments.

Beyond this, several other areas like precision medicine, next-generation therapeutics, longevity-focused therapies, and metabolic interventions are poised for growth. The next few years will likely witness a paradigm shift in healthcare, driven by these cutting-edge innovations. As an investor, I’m eager to support companies at the forefront of this transformation.

Like 1

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!